CTOs on the Move

Jeiven Pharmaceutical Consulting

www.jeiven.com

 
Jeiven Pharmaceutical Consulting is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.jeiven.com
  • 6 Jacobs Ln
    Scotch Plains, NJ USA 07076
  • Phone: 908.233.4508

Executives

Name Title Contact Details

Similar Companies

Lindus Health

Lindus Health is a next generation CRO that helps biotech and healthtech pioneers run faster, more reliable clinical trials. They provide end-to-end clinical trial services, including trial design, recruitment, and delivery, and have a unique technolog...

Epic Care

We are a dynamic organization committed to providing compassionate, high-quality healthcare across the Northern California East Bay.

Oramed

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

DMD Pharmaceuticals

DMD Pharmaceuticals is a Noblesville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Visus Therapeutics

Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.